Neoadjuvant Chemotherapy Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer (NSCLC) Interventions: Drug: Tislelizumab; Drug: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC); Drug: Carboplatin or Cisplatin; Procedure: Surgery Sponsors: The Affiliated Hospital of Qingdao University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials

PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY
Conditions: Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes Interventions: Drug: Tegafur Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
Conditions: Triple Negative Breast Cancer Interventions: Drug: Pembrolizumab; Drug: INBRX-106 Sponsors: Providence Health& Services; Inhibrx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Conditions: Gastric Cancer; Gastric Cancer Metastatic to Regional Lymph Nodes Interventions: Drug: Sintilimab; Radiation: Extraperitoneal radiation therapy; Drug: Oxaliplatin; Drug: S-1 Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Conditions: Breast Cancer; Axillary Metastases Interventions: Procedure: Targeted axillary dissection (TAD) by ICG; Procedure: Targeted axillary dissection (TAD) by Blue patent Sponsors: Hospital Universitari de Bellvitge Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials

Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Conditions: Muscle-Invasive Bladder Carcinoma Interventions: Combination Product: neoadjuvant chemotherapy Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
Conditions: Locally Advanced Rectal Carcinoma Interventions: Drug: Tislelizumab Sponsors: Beijing Friendship Hospital; Beijing Chao Yang Hospital; Peking University Cancer Hospital& Institute; CHINA-JAPEN FRIENDSHIP HOSPITAL; Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Fudan University; Changhai Hospital; RenJi Hospital; Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine; Shandong Provincial Hospital; Zhongnan Hospital of Wuhan University& Second Clinical Hospital of Wuhan University; The First Affiliated Hospital of Zhengzhou...
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Conditions: Gastric Cancer; Esophagogastric Junction Cancer Interventions: Drug: Cadonilimab; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Conditions: Breast Neoplasms Interventions: Drug: Carrellizumab + Capecitabine; Drug: Placebo + Capecitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma; Radiotherapy; Complications; IMMUNOTHERAPY Interventions: Radiation: de-escalated radiotherapy; Radiation: conventional radiotherapy Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Cancer Interventions: Drug: Combination of pembrolizumab and platinum containing dual drugs Sponsors: Tongji University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
Conditions: Ovarian Cancer Interventions: Behavioral: Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials

A Single Arm, Single Center, Phase II Clinical Study of Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Cancer Interventions: Drug: Combination of pembrolizumab and platinum containing dual drugs Sponsors: Tongji University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: paclitaxel; Drug: carboplatin; Drug: tislelizumab; Radiation: radiotherapy Sponsors: Qiu Guoqin Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Conditions: Locally Advanced Rectal Cancer Interventions: Combination Product: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor; Combination Product: Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor Sponsors: Beijing Friendship Hospital; Peking Union Medical College Hospital; Peking University Cancer Hospital& Institute; Changhai Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials